Copy
View this email in your browser
Share Share
Tweet Tweet
Forward Forward

The Web's Daily Resource for Epidermolysis Bullosa News

In the 05/31/2022 edition:

PTR-01 Promotes Wound Healing, Eases Pain in Phase 2 RDEB Trial

By Marisa Wexler MS on 05/27/2022

PTR-01 | Epidermolysis Bullosa News | illustration of chart for clinical trialTreatment with the experimental protein replacement therapy PTR-01 promoted wound healing and decreased pain in people with recessive dystrophic epidermolysis bullosa (RDEB), new results from a Phase 2 clinical trial show. The findings were presented by BridgeBio Pharma and its affiliate, Phoenix Tissue Repair, the therapy’s developer, at the annual meeting of the Society for Investigative […]

The post PTR-01 Promotes Wound Healing, Eases Pain in Phase 2 RDEB Trial appeared first on Epidermolysis Bullosa News.

Continue Reading

More Recent Articles:

EU Grants Orphan Drug Designation to Cannabinoid Cream PPP004 for EB
Three Cases of Severe Lung Involvement in Children With JEB
Organizations Rally to Help Ukrainian Rare Disease Patients
Put Courage Into Those Facing Hard Battles
Panel Supports Filsuvez Gel Approval in Europe for DEB, JEB

Follow us on social media for access to exclusive content!
Facebook
LinkedIn
Instagram
Copyright © 2022 BioNews Inc., All rights reserved.




Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.